SCHEMBL146544

SCHEMBL146544

CCNc1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
HPGD P15428 2/20 0.50
RAPGEF4 Q8WZA2 1/20 0.47
MAPT P10636 5/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 2/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NOS1 P29475 1/20 0.43
IDO1 P14902 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5728329 0.98 HPGD (0.49) MEN1KMT2AHPGDRAPGEF4MAPT
SCHEMBL6235610 0.85 MAPT (0.50) MEN1KMT2AHPGDRAPGEF4MAPT
SCHEMBL22139422 0.84 HPGD (0.45) MEN1KMT2AHPGDRAPGEF4MAPT
SCHEMBL3363357 0.84 MAPT (0.50) MEN1KMT2AHPGDMAPTCYP1A2
Hydrochloric Acid SCHEMBL5857094 0.83 MAPT (0.48) MEN1KMT2AHPGDRAPGEF4MAPT
SCHEMBL27642277 0.82 F2R (0.48) MEN1KMT2AHPGDRAPGEF4MAPT
SCHEMBL6231348 0.80 ABL1 (0.49) MEN1KMT2AHPGDRAPGEF4MAPT
Fluorobenzene SCHEMBL27677650 0.80 LMNA (0.52) MAPTCYP1A2CYP2C19ALDH1A1GAA
SCHEMBL18739788 0.80 ALDH1A1 (0.40) MEN1KMT2AHPGDRAPGEF4MAPT
SCHEMBL19968723 0.79 ABL1 (0.51) MEN1KMT2AHPGDMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120049017-A Org/ZnSO4Electrolyte, preparation method thereof and application of electrolyte in secondary battery 同济大学 2025-05-27 CN claimed
CN-114420852-B Preparation method of pure-phase RP perovskite film 河北工业大学 2025-05-27 CN claimed
CN-120004697-A Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material 同济大学 2025-05-16 CN claimed
CN-119726348-A Near-infrared perovskite laser and preparation method thereof 中国科学院半导体研究所 2025-03-28 CN claimed
CN-119726347-A Non-external-cavity near-infrared perovskite laser and preparation method thereof 中国科学院半导体研究所 2025-03-28 CN claimed
CN-119431706-A Fatigue-resistant polyurethane elastomer and preparation method and application thereof 万勋科技(深圳)有限公司 2025-02-14 CN claimed
CN-119371337-A Metal halide perovskite nanocrystalline resistant to heat-induced fluorescence quenching, and preparation method and application thereof 华南理工大学 2025-01-28 CN claimed
CN-118507836-B Electrolyte for secondary lithium metal battery 深圳欣界能源科技有限公司 2024-09-17 CN claimed
CN-118531514-A Mixed-dimension perovskite/polymer composite filament, preparation method and application 武汉纺织大学 2024-08-23 CN claimed
CN-118531558-A Mixed-dimension perovskite nanofiber membrane with high fluorescence stability and preparation method thereof 武汉纺织大学 2024-08-23 CN claimed
US-20160362427-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2016-12-15 US claimed
US-20130143824-A1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH, INC. (US) 2013-06-06 US claimed
US-20120058953-A1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH, INC. (US) 2012-03-08 US claimed
US-20110039324-A1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH, INC. (US) 2011-02-17 US claimed
US-20090148921-A1 Compositions and methods for enhancing apoptosis GENENTECH, INC. (US) 2009-06-11 US claimed
EP-1590666-B1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH INC (US) 2008-07-09 EP claimed
EP-1590666-A4 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH INC (US) 2006-07-26 EP claimed
EP-1590666-A1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS Genentech, Inc. (US) 2005-11-02 EP claimed
US-20040171554-A1 Compositions and methods for enhancing apoptosis GENENTECH, INC. 2004-09-02 US claimed
WO-2004072641-A1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH, INC. (US) 2004-08-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362427-A1 BRIDGED BICYCLIC KALLIKREIN INHIBITORS KLKB1, KLK1, KLK2 MEN1 1461/4885KMT2A 1323/4885HPGD 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.